文献速递妇科生殖医学

多囊卵巢综合征女性代谢综合征及其组分患病率的种族与民族差异:一项区域横断面研究

Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: a regional cross-sectional study.
PubMed 文献 · Am J Obstet Gynecol · 2017-04-08

该横断面研究纳入美国、印度、巴西、芬兰和挪威5国门诊1089例多囊卵巢综合征女性,比较代谢综合征及其组分聚集的种族差异。以美国白人女性为参照,美国黑人女性年龄调整后代谢综合征比值比为4.52,印度女性年龄和体重指数调整后比值比为6.53,挪威女性为2.16。

要点

  • 美国黑人女性年龄调整后代谢综合征比值比最高,为4.52(95%CI 2.46-8.35)。
  • 印度女性年龄和体重指数调整后代谢综合征比值比为6.53(95%CI 3.47-12.30)。
  • 挪威女性年龄和体重指数调整后代谢综合征比值比为2.16(95%CI 1.17-3.98)。

核心结论

  • 尽管多囊卵巢综合征诊断统一,但代谢综合征患病率及其组分聚集因种族和民族而异,可能反映种族和环境因素的双重作用。
  • 与美国白人女性相比,美国黑人女性代谢综合征患病率最高,印度和挪威女性代谢综合征患病率较高且独立于肥胖。
  • 代谢综合征组分聚集的种族差异凸显了常规进行完整代谢筛查以识别心血管风险降低策略具体靶点的必要性。

研究设计与样本

  • 横断面研究,纳入1999年至2016年在美国、印度、巴西、芬兰和挪威5个门诊诊所的1089例多囊卵巢综合征女性。
  • 多囊卵巢综合征采用鹿特丹标准定义。
  • 以美国白人多囊卵巢综合征女性为参照组,采用逻辑回归模型评估种族与代谢综合征患病率及其组分之间的关联,并调整年龄和体重指数等潜在混杂因素。

主要发现

  • 整个队列中位年龄为28岁。
  • 印度女性临床高雄激素血症的Ferriman-Gallwey评分均值最高,为15.6±6.5(P<.001)。
  • 美国黑人女性年龄调整后代谢综合征比值比为4.52(95%CI 2.46-8.35),高于美国白人女性;调整年龄和体重指数后,两组患病率相似。
  • 美国黑人女性中显著更多满足体重指数和血压标准(P<.001),更少满足空腹甘油三酯标准(P<.05)。
  • 印度女性年龄和体重指数调整后代谢综合征患病率最高(比值比6.53,95%CI 3.47-12.30),异常涉及血糖和空腹高密度脂蛋白胆固醇标准;挪威女性比值比为2.16(95%CI 1.17-3.98),异常涉及血压、血糖和空腹高密度脂蛋白胆固醇标准。

关键数值与推荐

  • 多囊卵巢综合征诊断采用鹿特丹标准。
  • 主要结局指标为代谢综合征患病率、血压、体重指数、空腹高密度脂蛋白胆固醇、空腹甘油三酯和空腹血糖。

临床怎么用

  • 原文结论指出,代谢综合征组分聚集的种族差异凸显了常规进行完整代谢筛查以识别心血管风险降低策略具体靶点的必要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polycystic ovary syndrome is a heterogeneous disorder and its presentation varies with race and ethnicity. Reproductive-age women with polycystic ovary syndrome are at increased risk of metabolic syndrome; however, it is not clear if prevalence of metabolic syndrome and clustering of its components differs based on race and ethnicity. Moreover, the majority of these women do not undergo routine screening for metabolic syndrome. OBJECTIVE: We sought to compare the prevalence of metabolic syndrome and clustering of its components in women with polycystic ovary syndrome in the United States with women in India, Brazil, Finland, and Norway. STUDY DESIGN: This is a cross-sectional study performed in 1089 women with polycystic ovary syndrome from 1999 through 2016 in 5 outpatient clinics in the United States, India, Brazil, Finland, and Norway. Polycystic ovary syndrome was defined by the Rotterdam criteria. Main outcome measures were: metabolic syndrome prevalence, blood pressure, body mass index, fasting high-density lipoprotein cholesterol, fasting triglycerides, and fasting glucose. Data from all sites were reevaluated for appropriate application of diagnostic criteria for polycystic ovary syndrome, identification of polycystic ovary syndrome phenotype, and complete metabolic workup. The US White women with polycystic ovary syndrome were used as the referent group. Logistic regression models were used to evaluate associations between race and metabolic syndrome prevalence and its components and to adjust for potential confounders, including age and body mass index. RESULTS: The median age of the entire cohort was 28 years. Women from India had the highest mean Ferriman-Gallwey score for clinical hyperandrogenism (15.6 ± 6.5, P < .001). The age-adjusted odds ratio for metabolic syndrome was highest in US Black women at 4.52 (95% confidence interval, 2.46-8.35) compared with US White women. When adjusted for age and body mass index, the prevalence was similar in the 2 groups. Significantly more Black women met body mass index and blood pressure criteria (P < .001), and fewer met fasting triglycerides criteria (P < .05). The age- and body mass index-adjusted prevalence of metabolic syndrome was highest in Indian women (odds ratio, 6.53; 95% confidence interval, 3.47-12.30) with abnormalities in glucose and fasting high-density lipoprotein cholesterol criterion and in Norwegian women (odds ratio, 2.16; 95% confidence interval, 1.17-3.98) with abnormalities in blood pressure, glucose, and fasting high-density lipoprotein cholesterol criterion. The Brazilian and Finnish cohorts had similar prevalence of metabolic syndrome and its components compared to US White women. CONCLUSION: Despite a unifying diagnosis of polycystic ovary syndrome, there are significant differences in the prevalence of metabolic syndrome and clustering of its components based on race and ethnicity, which may reflect contributions from both racial and environmental factors. Our findings indicate the prevalence of metabolic syndrome components varies in women with polycystic ovary syndrome, such that compared to White women from the United States, Black US women had the highest prevalence, whereas women from India and Norway had a higher prevalence of metabolic syndrome independent of obesity. The differences in clustering of components of metabolic syndrome based on ethnicity highlight the need to routinely perform complete metabolic screening to identify specific targets for cardiovascular risk reduction strategies in these reproductive-age women.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chan JL, Kar S, Vanky E, et al. Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: a regional cross-sectional study. Am J Obstet Gynecol. 2017. PMID: 28400308. doi:10.1016/j.ajog.2017.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。